Drug intelligence / Profile preview

BWC2094

Development stage: Preclinical
Lead developer: Bugworks Research
Modality: Small Molecules
Administration: Oral

Overview

BWC2094 is a small molecule dual antagonist of the adenosine A2A and A2B receptors (A2AR/A2BR) currently in preclinical development by Bugworks Research. Described as a "triple effector" agent, it is designed to target the adenosine axis within the tumor microenvironment to overcome immunosuppression. By blocking both A2AR and A2BR, BWC2094 aims to enhance the activity of T-cells and NK-cells while potentially exerting direct effects on tumor growth and metastasis. The program is focused on treating various solid tumors, including colorectal cancer, non-small cell lung cancer, triple-negative breast cancer, and pancreatic cancer.

Targets

ADORA2B (Adenosine A2B receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA3 (Adenosine A3 receptor)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on BWC2094.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BWC2094.

Explore the full profile